S&P 500
7,696.65
+30.05
+0.39%
Dow
53,323.76
+261.81
+0.49%
Nasdaq
26,403.47
+185.64
+0.71%
NYSE Composite
24,615.97
+120.42
+0.49%
Russell 2000
2,963.86
+10.70
+0.36%
VIX
15.09
-0.11
-0.72%
RZLT · Rezolute, Inc. Common Stock (NV)
NASDAQ NMS - GLOBAL MARKET - Real Time Price • USD
Rezolute Inc (RZLT)
NASDAQ NMS - GLOBAL MARKET
Biotechnology
$4.50
-0.08
(-1.64%)
● Market open
DAY'S RANGE
$4.50
$4.50
$4.55
52-WEEK RANGE
$4.50
$1.07
$11.46
What's happening
- RZLT is down 1.64% today, trading at $4.50. — Live quote
- Volume today (3,334) is well below its 3-month average of 1,694,300. (Finnhub fundamentals)
- Reports earnings on 2026-09-15 (after market close), 12 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $-0.16 actual vs. $-0.18 estimated (+12.3%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 6
Buy 7
Hold 3
Sell 0
Strong sell 0
Aggregate ratings for 2026-09-01 (16 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
RZLT
+93.22%
vs S&P 500
+81.01%
1-YEAR RETURN
RZLT
-37.02%
vs S&P 500
-55.88%
6-MONTH RETURN
RZLT
+42.06%
3-MONTH RETURN
RZLT
+14.00%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-04-26 (Q3 2026)
$-0.16
Est. $-0.18
BEAT +12.3%
2026-01-26 (Q2 2026)
$-0.22
Est. $-0.19
MISS -15.4%
2025-10-26 (Q1 2026)
$-0.18
Est. $-0.27
BEAT +33.4%
2025-07-26 (Q4 2025)
$-0.26
Est. $-0.22
MISS -15.9%
Valuation Measures & Ratios
Enterprise Value4$431.7M
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)—
Price / Book72.50
EV4 / Revenue—
EV4 / EBITDA—
Profit Margin—
Operating Margin—
Return on Equity (ROE8)-58.82%
Return on Assets (ROA9)-54.48%
Avg Volume (3M)1,694,300
Quarterly history (5 periods)
| Measure | Mar '26 | Dec '25 | Sep '25 | Mar '25 | Dec '24 |
|---|---|---|---|---|---|
| Market cap | $307.2M | $244.8M | $948.3M | $203.9M | $350.4M |
| P/E | -4.04 | -3.24 | -13.91 | -3.04 | -5.64 |
| Price/Book | 2.63 | 1.91 | 6.44 | 2.47 | 3.52 |
| ROE | -65.06% | -59.04% | -46.32% | -81.23% | -62.32% |
| ROA | -60.58% | -54.51% | -42.97% | -70.80% | -55.41% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E and PEG aren't shown here — both need historical analyst-consensus estimates, which no free source provides; see the current-period figures above instead.
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short16,524,214
Change from Prior Settlement-2.12%
% of Float—
Days to Cover (Short Ratio)13.34
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-08-14. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Signals describe daily price patterns—not the company’s value and not a recommendation to buy or sell. Read several together; no single indicator predicts what happens next. “Overbought” and “oversold” are conditions, not promises of a reversal.
Indicators None active
Loading chart…
Free IEX historical data only goes back to ~2021 — 5Y/Full show whatever's actually available, not a promise of that much history. Indicators are computed client-side from these same price bars; earnings markers ("E") come from Finnhub's free tier (~last 4 quarters + next upcoming) — older quarters aren't available. The move-highlight dots are a heuristic (|% change| vs rolling volatility) with a best-effort headline lookup, not a claim of causation.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Latest SEC filing is Form 4, filed 2026-07-07; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Trailing 52-week price return is -37.0%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on RZLT
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Mar '26 | Dec '25 | Sep '25 | Mar '25 | Dec '24 | Sep '24 | Mar '24 | Dec '23 |
|---|---|---|---|---|---|---|---|---|
| Operating income | -$17.4M | -$24.2M | -$19.8M | -$20.0M | -$17.1M | -$16.9M | -$16.2M | -$15.2M |
| Net income | -$16.2M | -$22.8M | -$18.1M | -$18.9M | -$15.7M | -$15.4M | -$17.1M | -$13.9M |
| EPS (diluted) | $-0.16 | $-0.22 | $-0.18 | $-0.27 | $-0.22 | $-0.22 | $-0.34 | $-0.27 |
| EPS (basic) | $-0.16 | $-0.22 | $-0.18 | $-0.27 | $-0.22 | $-0.22 | $-0.34 | $-0.27 |
Balance sheet
| Line item | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $125.5M | $138.6M | $158.7M | $175.5M | $94.7M | $112.0M | $123.4M | $132.7M |
| Total liabilities | $8.6M | $10.6M | $11.5M | $13.4M | $12.2M | $12.4M | $10.0M | $11.7M |
| Stockholders' equity | $116.8M | $128.0M | $147.2M | $162.1M | $82.6M | $99.6M | $113.4M | $121.0M |
| Total current assets | $122.0M | $135.1M | $154.7M | $171.1M | $88.7M | $98.7M | $110.2M | $128.7M |
| Total current liabilities | $7.7M | $9.5M | $10.2M | $11.9M | $10.5M | $10.6M | $8.0M | $9.6M |
| Cash & equivalents | $11.2M | $11.9M | $9.1M | $94.1M | $14.6M | $8.9M | $10.5M | $70.4M |
| Marketable securities (current) | $109.0M | $121.0M | $143.1M | $73.8M | $72.3M | $87.6M | $97.8M | $56.5M |
| Inventory | — | — | — | — | — | — | — | — |
| Other current assets | — | — | — | — | — | — | — | — |
| Marketable securities (non-current) | $0 | $0 | $0 | — | $1.5M | $8.8M | $9.6M | $263.0K |
| Property, plant & equipment | $49.0K | $57.0K | $64.0K | $72.0K | $80.0K | $87.0K | $95.0K | $103.0K |
| Intangible assets | — | — | — | — | — | — | — | — |
| Other non-current assets | — | — | — | — | — | — | — | — |
| Accounts payable | $3.2M | $3.8M | $3.3M | $5.8M | $6.5M | $3.1M | $2.2M | $4.9M |
| Short-term debt | — | — | — | — | — | — | — | — |
| Other current liabilities | — | — | — | — | — | — | — | — |
| Long-term debt | — | — | — | — | — | — | — | — |
| Other non-current liabilities | — | — | — | — | — | — | — | — |
| Common stock & paid-in capital | $96.0K | $96.0K | $91.0K | $87.0K | $61.0K | $61.0K | $55.0K | $53.0K |
| Retained earnings | -$461.0M | -$444.8M | -$422.0M | -$403.9M | -$379.5M | -$360.6M | -$344.8M | -$329.4M |
| Accumulated other comprehensive income (loss) | -$115.0K | $47.0K | $49.0K | -$7.0K | $43.0K | $64.0K | $289.0K | -$79.0K |
Cash flow
| Line item | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$13.7M | -$20.3M | -$17.4M | -$22.0M | -$17.4M | -$13.7M | -$16.0M | -$18.5M |
| Investing cash flow | $12.3M | $22.8M | -$68.5M | $346.0K | $23.1M | $11.5M | -$49.4M | $19.7M |
| Financing cash flow | $747.0K | $356.0K | $911.0K | $101.2M | $10.0K | $657.0K | $5.5M | $63.3M |
| Capital expenditures | — | — | — | — | — | — | — | — |
| Share-based compensation | $4.4M | $3.4M | $2.5M | $2.4M | $1.9M | $1.4M | $1.4M | $1.8M |
| Deferred income taxes | — | — | — | — | — | — | — | — |
| Change in inventory | — | — | — | — | — | — | — | — |
| Change in accounts payable | -$587.0K | $524.0K | -$2.5M | -$730.0K | $3.4M | $991.0K | -$2.2M | $853.0K |
| Purchases of investments | $37.0M | $26.8M | $88.9M | $27.5M | $2.0M | $25.4M | $73.2M | $9.7M |
| Sales/maturities of investments | — | — | — | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | — | $0 |
Income statement
| Line item | Jun '25 | Jun '24 | Jun '23 | Jun '22 | Jun '21 |
|---|---|---|---|---|---|
| Operating income | -$79.9M | -$70.4M | -$56.0M | -$41.8M | -$22.9M |
| Net income | -$74.4M | -$68.5M | -$51.8M | -$41.1M | -$20.9M |
| EPS (diluted) | $-0.98 | $-1.33 | $-1.01 | $-2.32 | $-2.72 |
| EPS (basic) | $-0.98 | $-1.33 | $-1.01 | $-2.26 | $-2.72 |
Balance sheet
| Line item | Jun '25 | Jun '24 | Jun '23 | Jun '22 | Jun '21 |
|---|---|---|---|---|---|
| Total assets | $175.5M | $132.7M | $123.7M | $152.4M | $42.6M |
| Total liabilities | $13.4M | $11.7M | $7.5M | $2.9M | $16.5M |
| Stockholders' equity | $162.1M | $121.0M | $116.2M | $149.5M | $26.1M |
| Total current assets | $171.1M | $128.7M | $104.9M | $152.1M | $42.0M |
| Total current liabilities | $11.9M | $9.6M | $5.2M | $2.5M | $2.0M |
| Cash & equivalents | $94.1M | $70.4M | $16.0M | $150.4M | $41.0M |
| Marketable securities (current) | $73.8M | $56.5M | $85.9M | — | — |
| Inventory | — | — | — | — | — |
| Other current assets | — | — | — | — | — |
| Marketable securities (non-current) | — | $263.0K | $16.5M | — | — |
| Property, plant & equipment | $72.0K | $103.0K | $139.0K | $16.0K | $29.0K |
| Intangible assets | — | — | — | — | — |
| Accounts payable | $5.8M | $4.9M | $3.3M | $1.1M | $1.0M |
| Other current liabilities | — | — | — | $979.0K | $349.0K |
| Long-term debt | — | — | — | — | $14.0M |
| Other non-current liabilities | — | — | — | — | — |
| Common stock & paid-in capital | $87.0K | $53.0K | $37.0K | $34.0K | $8.0K |
| Retained earnings | -$403.9M | -$329.4M | -$261.0M | -$209.2M | -$168.1M |
| Accumulated other comprehensive income (loss) | -$7.0K | -$79.0K | -$351.0K | — | — |
Cash flow
| Line item | Jun '25 | Jun '24 | Jun '23 | Jun '22 | Jun '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$69.1M | -$57.4M | -$44.5M | -$39.6M | -$20.4M |
| Investing cash flow | -$14.5M | $48.7M | -$101.5M | — | $0 |
| Financing cash flow | $107.3M | $63.0M | $11.6M | $149.0M | $51.5M |
| Free cash flow | — | — | -$44.6M | — | — |
| Capital expenditures | — | — | $153.0K | — | — |
| Share-based compensation | $7.1M | $7.4M | $7.3M | $3.7M | $4.0M |
| Deferred income taxes | — | — | — | — | — |
| Change in inventory | — | — | — | — | — |
| Change in accounts payable | $1.4M | $1.1M | $2.1M | -$11.0K | $142.0K |
| Purchases of investments | $128.1M | $66.4M | $107.3M | — | — |
| Sales/maturities of investments | — | — | $0 | — | — |
| Share repurchases | — | $3.0K | — | — | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding RZLT as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Source: Business Quant SEC Form 13F · report period 2026-06-30 · 31 filers
Held by These Filers74.5%
Shares Outstanding104,040,292
| Filer | Shares | Value | % Out | Qtr Change | Filed |
|---|---|---|---|---|---|
| Federated Hermes, Inc. | 12,990,659 | $67.6M | 12.49% | +0.0% | 2026-08-12 |
| RA CAPITAL MANAGEMENT, L.P. | 9,445,039 | $49.1M | 9.08% | +2.9% | 2026-08-14 |
| BlackRock, Inc. | 7,718,291 | $40.1M | 7.42% | +22.3% | 2026-08-07 |
| Opaleye Management Inc. | 6,300,000 | $32.8M | 6.06% | +0.0% | 2026-08-14 |
| BALYASNY ASSET MANAGEMENT L.P. | 4,662,039 | $24.2M | 4.48% | -7.7% | 2026-08-13 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3,835,827 | $19.9M | 3.69% | +8.9% | 2026-06-30 |
| Siren, L.L.C. | 3,328,287 | $17.3M | 3.20% | +0.0% | 2026-08-13 |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 2,561,654 | $13.3M | 2.46% | +1062.2% | 2026-08-12 |
| JENNISON ASSOCIATES LLC | 2,459,308 | $12.8M | 2.36% | -28.5% | 2026-08-03 |
| GEODE CAPITAL MANAGEMENT, LLC | 2,170,154 | $11.3M | 2.09% | +10.5% | 2026-08-12 |
| State Street Corp | 1,850,128 | $9.6M | 1.78% | +4.4% | 2026-08-07 |
| D. E. Shaw & Co., Inc. | 1,839,357 | $9.6M | 1.77% | +4.2% | 2026-08-14 |
| Morgan Stanley | 1,618,783 | $8.4M | 1.56% | -41.1% | 2026-08-11 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 1,380,746 | $7.2M | 1.33% | -53.7% | 2026-06-30 |
| Goldman Sachs Group Inc | 1,316,782 | $6.8M | 1.27% | +118.6% | 2026-08-14 |
| Nuveen, LLC | 1,295,209 | $6.7M | 1.24% | +1225.9% | 2026-08-11 |
| KENNEDY CAPITAL MANAGEMENT LLC | 1,221,678 | $6.4M | 1.17% | -1.2% | 2026-08-14 |
| Blackstone Inc. | 1,082,927 | $5.6M | 1.04% | +0.0% | 2026-08-14 |
| AQR CAPITAL MANAGEMENT LLC | 1,007,962 | $5.2M | 0.97% | +26.5% | 2026-08-14 |
| Affinity Asset Advisors, LLC | 1,000,000 | $5.2M | 0.96% | -35.4% | 2026-08-13 |
| GREAT POINT PARTNERS LLC | 951,809 | $4.9M | 0.91% | +0.0% | 2026-08-14 |
| Ikarian Capital, LLC | 935,012 | $4.9M | 0.90% | +5574.0% | 2026-08-14 |
| DIMENSIONAL FUND ADVISORS LP | 890,733 | $4.6M | 0.86% | +68.0% | 2026-08-11 |
| 22NW, LP | 820,653 | $4.3M | 0.79% | +0.0% | 2026-07-14 |
| Velan Capital Investment Management LP | 750,000 | $3.9M | 0.72% | +0.0% | 2026-08-14 |
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2025-06-24 to 2026-07-02
Recent transactions
- Insiders have net bought 10,000 shares over the last 182 days, across 1 purchase and 0 sales.
- Most recent: ROBERTS BRIAN KENNETH (Chief Medical Officer) — Tax withholding of 3,062 shares on 2026-07-02.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)10,000 sh(1 txns)
Sales (open market)0 sh(0 txns)
Net Shares+10,000
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| ROBERTS BRIAN KENNETH | Chief Medical Officer | Tax withholding | 2026-07-02 | 3,062 |
| Elam Nevan C | CEO | Tax withholding | 2026-07-02 | 8,004 |
| Evans Daron | CFO | Tax withholding | 2026-07-02 | 3,062 |
| Hogenhuis Wladimir | Reporting person | Open market purchase | 2025-12-16 | 5,650 |
| Karnawat Sunil Ratilal | Chief Commercial Officer | Open market purchase | 2025-12-15 | 12,000 |
| KREHER NERISSA | Reporting person | Grant / award | 2025-11-19 | 21,000 |
| Harris Erik | Reporting person | Grant / award | 2025-11-19 | 21,000 |
| Kim Young-Jin | Reporting person | Grant / award | 2025-11-19 | 21,000 |
| FAUCHET PHILIPPE | Reporting person | Grant / award | 2025-11-19 | 21,000 |
| Labrucherie Gil M | Reporting person | Grant / award | 2025-11-19 | 21,000 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-07-02 | ROBERTS BRIAN KENNETH | Chief Medical Officer | Tax withholding | 3,062 | $4.99 |
| 2026-07-02 | Elam Nevan C | CEO | Tax withholding | 8,004 | $4.99 |
| 2026-07-02 | Evans Daron | CFO | Tax withholding | 3,062 | $4.99 |
| 2026-03-30 | Evans Daron | CFO | Open market purchase | 10,000 | $2.85 |
| 2026-03-02 | ROBERTS BRIAN KENNETH | Chief Medical Officer | Tax withholding | 11,439 | $2.99 |
| 2026-03-02 | Evans Daron | CFO | Tax withholding | 11,438 | $2.99 |
| 2026-03-02 | Elam Nevan C | CEO | Tax withholding | 27,618 | $2.99 |
| 2025-12-16 | Hogenhuis Wladimir | Reporting person | Open market purchase | 5,650 | $1.69 |
| 2025-12-16 | ROBERTS BRIAN KENNETH | Chief Medical Officer | Open market purchase | 28,000 | $1.70 |
| 2025-12-15 | Evans Daron | CFO | Open market purchase | 40,000 | $1.77 |
| 2025-12-15 | Evans Daron | CFO | Open market purchase | 2,500 | $1.78 |
| 2025-12-15 | Evans Daron | CFO | Open market purchase | 2,500 | $1.79 |
| 2025-12-15 | Elam Nevan C | CEO | Open market purchase | 32,000 | $1.59 |
| 2025-12-15 | Karnawat Sunil Ratilal | Chief Commercial Officer | Open market purchase | 12,000 | $1.62 |
| 2025-12-15 | Karnawat Sunil Ratilal | Chief Commercial Officer | Open market purchase | 100 | $1.60 |
| 2025-11-19 | ROBERTS BRIAN KENNETH | Chief Medical Officer | Grant / award | 123,000 | $0.00 |
| 2025-11-19 | Karnawat Sunil Ratilal | Chief Commercial Officer | Grant / award | 32,000 | $0.00 |
| 2025-11-19 | Elam Nevan C | CEO | Grant / award | 317,000 | $0.00 |
| 2025-11-19 | Evans Daron | CFO | Grant / award | 107,000 | $0.00 |
| 2025-11-19 | KREHER NERISSA | Reporting person | Grant / award | 21,000 | $0.00 |
| 2025-11-19 | Hogenhuis Wladimir | Reporting person | Grant / award | 21,000 | $0.00 |
| 2025-11-19 | Harris Erik | Reporting person | Grant / award | 21,000 | $0.00 |
| 2025-11-19 | Kim Young-Jin | Reporting person | Grant / award | 21,000 | $0.00 |
| 2025-11-19 | FAUCHET PHILIPPE | Reporting person | Grant / award | 21,000 | $0.00 |
| 2025-11-19 | Labrucherie Gil M | Reporting person | Grant / award | 21,000 | $0.00 |
| 2025-08-18 | Karnawat Sunil Ratilal | Chief Commercial Officer | Grant / award | 25,000 | $0.00 |
| 2025-06-25 | ROBERTS BRIAN KENNETH | Chief Medical Officer | Open market purchase | 2,500 | $4.38 |
| 2025-06-24 | Evans Daron | CFO | Open market purchase | 5,000 | $4.05 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-09-03 11:49 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-07-07 | 4 | 2026-07-02 | View on SEC.gov → |
| 2026-07-07 | 4 | 2026-07-02 | View on SEC.gov → |
| 2026-07-07 | 4 | 2026-07-02 | View on SEC.gov → |
| 2026-06-02 | 8-K | 2026-06-02 | View on SEC.gov → |
| 2026-05-12 | 10-Q | 2026-03-31 | View on SEC.gov → |
| 2026-05-12 | 8-K | 2026-05-12 | View on SEC.gov → |
| 2026-05-04 | 8-K | 2026-05-01 | View on SEC.gov → |
| 2026-03-31 | 4 | 2026-03-30 | View on SEC.gov → |
| 2026-03-24 | 8-K | 2026-03-24 | View on SEC.gov → |
| 2026-03-04 | 4 | 2026-03-02 | View on SEC.gov → |
| 2026-03-04 | 4 | 2026-03-02 | View on SEC.gov → |
| 2026-03-04 | 4 | 2026-03-02 | View on SEC.gov → |
Recent news
Headlines about RZLT (Rezolute, Inc. Common Stock (NV)). Links open the publisher — we don’t host full articles.
-
MARA Holdings, Coinbase Global, Ternium And Other Big Stocks Moving Higher On Friday
Benzinga · 2026-08-21 -
Rezolute to Participate in the BTIG Virtual Biotechnology Conference
Yahoo Finance · 2026-07-21 -
Rezolute Highlights Results Presented from Natural History Outcomes Studies and its Ersodetug Clinical Program in Hyperinsulinism at Annual Meeting of the Endocrine Society
Yahoo Finance · 2026-06-17 -
Exploring 3 High Growth Tech Stocks in US Market
Yahoo Finance · 2026-06-15 -
Positive Signs As Multiple Insiders Buy Rezolute Stock
Yahoo Finance · 2026-06-10 -
RZLT Stock on the Move: What Sparks the 38% Jump in the Past Week?
Yahoo Finance · 2026-06-04 -
Rezolute Announces Four Presentations at the Upcoming Annual Meeting of the Endocrine Society
Yahoo Finance · 2026-06-04 -
Rezolute upgraded at Citizens after late-stage trial data for lead asset
Seeking Alpha · 2026-06-03
No headlines in this category right now — try “All”.